All inspectors · Key sources (PDF) · Antithrombotics sheet (PDF)
The Antithrombotic Therapy Around PCI one-pagerOpen it in a new tab

The patient in front of you

Mrs. K., 77, with hypertension, presented with 5 hours of chest pain at rest, ST depression in V2–V4 and a rising troponin. Angiography the next day showed a single 90% stenosis of the proximal left anterior descending artery, treated with a drug-eluting stent by radial access. She was loaded with aspirin and ticagrelor. She has never bled and takes no anticoagulant; eGFR 48, hemoglobin 12.6 g/dL, platelets 214, ejection fraction 55%, sinus rhythm. Three weeks after PCI, new atrial fibrillation was found (no other change): a DOAC was started, ticagrelor was changed to clopidogrel and aspirin was stopped, and she has taken the DOAC and clopidogrel since. Today is her 12-month visit: she is stable and still in atrial fibrillation.

This page helps you decide: At her 12-month visit, still in atrial fibrillation: keep clopidogrel with the anticoagulant, or the anticoagulant alone from here on?

After this page you can

Your routine for every trial

Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.

  1. Who was studied? Which patients could enter, which could not, and how sick were they?
  2. Compared with what? What did one group get that the other did not, and what was measured?
  3. What was the main result? Both percentages, the effect size with its 95% CI, and the number needed to treat (and to harm).
  4. Any design traps? Blinding, the choice of endpoint, how close the CI comes to no effect, how long it took, who paid.
  5. Does it apply to my patient? Would my patient have been allowed into the trial?
  6. What did it change? What the guideline now says, and what the trial does not tell you.

Take-home

For Mrs. K. at 12 months, EPIC-CAD supports edoxaban alone over edoxaban plus an antiplatelet: about one patient spared a net adverse event for every 11 treated for a year, driven by bleeding avoided, with major ischemic events appearing similar. Read it knowing the trial was open-label, ran for 12 months in South Korea, enrolled few women, and that her edoxaban dose depends on her creatinine clearance and weight. On the one-pager it sits on page 3, in the “On an oral anticoagulant — the trials” box (the ‘After 1 year’ row), with the Class 1 line in the recommendations box on the same page.